Ian Hastings

List of Publications by Year
in descending order

109 papers	3,955 citations	101384 36 h-index	143772 57 g-index
117 all docs	117 docs citations	117 times ranked	3803 citing authors

#	Article	IF	Citations
1	THE IMPORTANCE OF MOSQUITO BEHAVIOURAL ADAPTATIONS TO MALARIA CONTROL IN AFRICA. Evolution; International Journal of Organic Evolution, 2013, 67, 1218-1230.	1.1	253
2	The evolution of drug–resistant malaria: the role of drug elimination half–life. Philosophical Transactions of the Royal Society B: Biological Sciences, 2002, 357, 505-519.	1.8	170
3	ANTIMALARIAL DRUG RESISTANCE, ARTEMISININ-BASED COMBINATION THERAPY, AND THE CONTRIBUTION OF MODELING TO ELUCIDATING POLICY CHOICES. American Journal of Tropical Medicine and Hygiene, 2004, 71, 179-186.	0.6	148
4	Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infectious Diseases, The, 2007, 7, 136-144.	4.6	136
5	Allomonal effect of breath contributes to differential attractiveness of humans to the African malaria vector Anopheles gambiae. Malaria Journal, 2004, 3, 1.	0.8	110
6	Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. PLoS Neglected Tropical Diseases, 2015, 9, e0003822.	1.3	108
7	Population genetic aspects of deleterious cytoplasmic genomes and their effect on the evolution of sexual reproduction. Genetical Research, 1992, 59, 215-225.	0.3	106
8	The origins of antimalarial drug resistance. Trends in Parasitology, 2004, 20, 512-518.	1.5	100
9	Mutation and selection within the individual. Genetica, 1998, 102/103, 507-524.	0.5	90
10	Field, Genetic, and Modeling Approaches Show Strong Positive Selection Acting upon an Insecticide Resistance Mutation in Anopheles gambiae s.s.. Molecular Biology and Evolution, 2010, 27, 1117-1125.	3.5	88
11	Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies. Malaria Journal, 2008, 7, 229.	0.8	87
12	PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Molecular Microbiology, 2006, 62, 238-251.	1.2	85
13	Malaria and Irrigated Crops, Accra, Ghana. Emerging Infectious Diseases, 2005, 11, 1290-1293.	2.0	80
14	Tolerance is the key to understanding antimalarial drug resistance. Trends in Parasitology, 2006, 22, 71-77.	1.5	76
15	Intensity of malaria transmission and the evolution of drug resistance. Acta Tropica, 2005, 94, 218-229.	0.9	74
16	The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resistance Updates, 2005, 8, 43-50.	6.5	67
17	Malaria control and the evolution of drug resistance: an intriguing link. Trends in Parasitology, 2003, 19, 70-73.	1.5	64
18	Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. American Journal of Tropical Medicine and Hygiene, 2004, 71, 179-86.	0.6	64

#	Article	IF	Citations
19	Coartem (Artemetherâ€‹Lumefantrine) in Africa: The Beginning of the End?. Journal of Infectious Diseases, 2005, 192, 1303-1304.	1.9	61
20	Complex dynamics and stability of resistance to antimalarial drugs. Parasitology, 2006, 132, 615-24.	0.7	59
21	How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?. Antimicrobial Agents and Chemotherapy, 2015, 59, 6428-6436.	1.4	59
22	Laboratory risk factors for hospital mortality in acutely admitted patients. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 501-507.	0.2	58
23	The Plasmodium falciparum var gene switching rate, switching mechanism and patterns of parasite recrudescence described by mathematical modelling. Parasitology, 2002, 124, 225-235.	0.7	57
24	A Requiem for Chloroquine. Science, 2002, 298, 74-75.	6.0	57
25	Antibiotic Chemotherapy of Onchocerciasis: In a Bovine Model, Killing of Adult Parasites Requires a Sustained Depletion of Endosymbiotic Bacteria (WolbachiaSpecies). Journal of Infectious Diseases, 2005, 192, 1483-1493.	1.9	57
26	How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends in Parasitology, 2011, 27, 67-72.	1.5	51
27	Entomological indices of malaria transmission in Chikhwawa district, Southern Malawi. Malaria Journal, 2012, 11, 380.	0.8	50
28	Modelling parasite drug resistance: lessons for management and control strategies. Tropical Medicine and International Health, 2001, 6, 883-890.	1.0	49
29	Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Review of Anti-Infective Therapy, 2009, 7, 581-593.	2.0	49
30	Climate prediction of El NiÃ±o malaria epidemics in north-west Tanzania. Malaria Journal, 2007, 6, 162.	0.8	48
31	â€œSexualâ€‹Population Structure and Genetics of the Malaria Agent P. falciparum. PLoS ONE, 2007, 2, e613.	1.1	47
32	Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. International Journal for Parasitology, 2003, 33, 1051-1058.	1.3	40
33	ORIGINAL ARTICLE: Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evolutionary Applications, 2009, 2, 52-61.	1.5	40
34	Prediction of hospital mortality from admission laboratory data and patient age: A simple model. EMA - Emergency Medicine Australasia, 2011, 23, 354-363.	0.5	40
35	A Comparison of Methods to Detect and Quantify the Markers of Antimalarial Drug Resistance. American Journal of Tropical Medicine and Hygiene, 2010, 83, 489-495.	0.6	39
36	Development, Evaluation, and Application of an <i>In Silico</i> Model for Antimalarial Drug Treatment and Failure. Antimicrobial Agents and Chemotherapy, 2011, 55, 3380-3392.	1.4	39

#	Article	IF	Citations
37	THE SEARCH FOR EFFECTIVE AND SUSTAINABLE TREATMENTS FOR PLASMODIUM FALCIPARUM MALARIA IN AFRICA: A MODEL OF THE SELECTION OF RESISTANCE BY ANTIFOLATE DRUGS AND THEIR COMBINATIONS. American Journal of Tropical Medicine and Hygiene, 2005, 72, 163-173.	0.6	37
38	Insecticide resistance evolution with mixtures and sequences: a model-based explanation. Malaria Journal, 2018, 17, 80.	0.8	35
39	MalHaploFreq: A computer programme for estimating malaria haplotype frequencies from blood samples. Malaria Journal, 2008, 7, 130.	0.8	34
40	Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs. PLoS Computational Biology, 2013, 9, e1003151.	1.5	31
41	Analysis of lines of mice selected for fat content. 2. Correlated responses in the activities of enzymes involved in lipogenesis. Genetical Research, 1990, 55, 55-61.	0.3	30
42	Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness. Antimicrobial Agents and Chemotherapy, 2015, 59, 6419-6427.	1.4	29
43	Quantifying the Evolution and Impact of Antimalarial Drug Resistance: Drug Use, Spread of Resistance, and Drug Failure over a 12‑Year Period in Papua New Guinea. Journal of Infectious Diseases, 2010, 201, 435-443.	1.9	28
44	Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proceedings of the Royal Society B: Biological Sciences, 2011, 278, 1705-1712.	1.2	28
45	Challenges in Estimating Insecticide Selection Pressures from Mosquito Field Data. PLoS Neglected Tropical Diseases, 2011, 5, e1387.	1.3	27
46	Mathematical Models of Human African Trypanosomiasis Epidemiology. Advances in Parasitology, 2015, 87, 53-133.	1.4	27
47	Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment. Antimicrobial Agents and Chemotherapy, 2016, 60, 2747-2756.	1.4	26
48	A Two-Locus Model of the Evolution of Insecticide Resistance to Inform and Optimise Public Health Insecticide Deployment Strategies. PLoS Computational Biology, 2017, 13, e1005327.	1.5	26
49	The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infectious Diseases, The, 2007, 7, 739-748.	4.6	25
50	The importance of modelling the spread of insecticide resistance in a heterogeneous environment: the example of adding synergists to bed nets. Malaria Journal, 2012, 11, 258.	0.8	25
51	Pharmacological considerations in the design of anti-malarial drug combination therapies – is matching half-lives enough?. Malaria Journal, 2014, 13, 62.	0.8	24
52	Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malaria Journal, 2014, 13, 138.	0.8	23
53	The genetic basis of response in mouse lines divergently selected for body weight or fat content. I. The relative contributions of autosomal and sex-linked genes. Genetical Research, 1993, 62, 169-175.	0.3	22
54	The impact of endemic and epidemic malaria on the risk of stillbirth in two areas of Tanzania with different malaria transmission patterns. Malaria Journal, 2006, 5, 89.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance. Malaria Journal, 2010, 9, 8.	0.8	21
56	Measuring windows of selection for anti-malarial drug treatments. Malaria Journal, 2015, 14, 292.	0.8	21
57	PCR correction strategies for malaria drug trials: updates and clarifications. Lancet Infectious Diseases, The, 2020, 20, e20-e25.	4.6	21
58	Modelling the impact of insecticide-based control interventions on the evolution of insecticide resistance and disease transmission. Parasites and Vectors, 2018, 11, 482.	1.0	20
59	Models of human genetic disease: how biased are the standard formulae?. Genetical Research, 2000, 75, 107-114.	0.3	19
60	Impact of El Nino and malaria on birthweight in two areas of Tanzania with different malaria transmission patterns. International Journal of Epidemiology, 2004, 33, 1311-1319.	0.9	19
61	Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers *msp-1* , *msp-2* , and *glurp*. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
62	Analysis of lines of mice selected on fat content: 4. Correlated responses in growth and reproduction. Genetical Research, 1991, 58, 253-259.	0.3	18
63	The role of growth hormone in lines of mice divergently selected on body weight. Genetical Research, 1993, 61, 101-106.	0.3	18
64	Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. Tropical Medicine and International Health, 2006, 11, 1206-1217.	1.0	18
65	The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. American Journal of Tropical Medicine and Hygiene, 2005, 72, 163-73.	0.6	17
66	Can mutation and selection explain virulence in human P. falciparum infections?. Malaria Journal, 2004, 3, 2.	0.8	16
67	Analysing malaria drug trials on a perâ€individual or perâ€clone basis: aâ€‰comparison of methods. Statistics in Medicine, 2013, 32, 3020-3038.	0.8	16
68	The role of windows of selection and windows of dominance in the evolution of insecticide resistance in human disease vectors. Evolutionary Applications, 2020, 13, 738-751.	1.5	16
69	A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	15
70	A Lifetime Perspective on Foraging and Mortality. Journal of Theoretical Biology, 2002, 215, 385-397.	0.8	14
71	The genetic polymorphism of Plasmodium vivax genes in endemic regions of Thailand. Asian Pacific Journal of Tropical Medicine, 2011, 4, 931-936.	0.4	14
72	Quantifying the pharmacology of antimalarial drug combination therapy. Scientific Reports, 2016, 6, 32762.	1.6	14

#	ARTICLE	IF	CITATIONS
73	The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant Plasmodium falciparum. ELife, 0, 11, .	2.8	14
74	Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malaria Journal, 2012, 11, 422.	0.8	13
75	Variation in Calculating and Reporting Antimalarial Efficacy against Plasmodium falciparum in Sub-Saharan Africa: A Systematic Review of Published Reports. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1820-1829.	0.6	13
76	Why is sex so frequent?. Trends in Ecology and Evolution, 1992, 7, 278-279.	4.2	12
77	Increased postpartum blood loss in pregnancies associated with placental malaria. International Journal of Gynecology and Obstetrics, 2007, 96, 171-175.	1.0	12
78	The population genetics of alleles affecting enzyme activity. Journal of Theoretical Biology, 1992, 157, 305-316.	0.8	10
79	Reproductive compensation and human genetic disease. Genetical Research, 2001, 77, 277-83.	0.3	10
80	Should Deep-Sequenced Amplicons Become the New Gold Standard for Analyzing Malaria Drug Clinical Trials?. Antimicrobial Agents and Chemotherapy, 2021, 65, e0043721.	1.4	10
81	The genetic basis of response in mouse lines divergently selected for body weight or fat content. II. The contribution of genes with a large effect. Genetical Research, 1993, 62, 177-182.	0.3	9
82	Effects of thyroid hormone deficiency on mice selected for increased and decreased body weight and fatness. Genetical Research, 1998, 72, 39-53.	0.3	9
83	Why we should effectively treat malaria. Trends in Parasitology, 2011, 27, 51-52.	1.5	9
84	Markov chain Monte Carlo and expectation maximization approaches for estimation of haplotype frequencies for multiply infected human blood samples. Malaria Journal, 2016, 15, 430.	0.8	9
85	The Importance of Scientific Debate in the Identification, Containment, and Control of Artemisinin Resistance. Clinical Infectious Diseases, 2016, 63, 1527.1-1528.	2.9	9
86	Behavioural changes as a correlated response to selection. Genetical Research, 1995, 66, 27-33.	0.3	8
87	The effect of testosterone in mice divergently selected on fat content or body weight. Genetical Research, 1997, 70, 135-141.	0.3	8
88	Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance. Journal of Infectious Diseases, 2019, 219, 1243-1253.	1.9	8
89	Will ART rollout in Africa drive an epidemic of drug resistant HIV?. Aids, 2006, 20, 1354-1356.	1.0	7
90	Molecular markers as indicators of antimalarial drug failure rates. Tropical Medicine and International Health, 2007, 12, 1298-1301.	1.0	7

#	Article	IF	Citations
91	Improving the Role and Contribution of Pharmacokinetic Analyses in Antimalarial Drug Clinical Trials. Antimicrobial Agents and Chemotherapy, 2014, 58, 5643-5649.	1.4	7
92	Incorporating genetic selection into individual-based models of malaria and other infectious diseases. Evolutionary Applications, 2020, 13, 2723-2739.	1.5	7
93	Response to: The puzzling links between malaria transmission level and drug resistance. Trends in Parasitology, 2003, 19, 160-161.	1.5	6
94	Leukocytosis as an alarming sign for mortality in patients hospitalized in general wards. Iranian Journal of Medical Sciences, 2011, 36, 45-9.	0.3	6
95	Genetics and malaria â€" more questions than answers. Trends in Parasitology, 2001, 17, 55-56.	1.5	5
96	Male-specific insecticide resistance and mosquito transgene dispersal. Trends in Parasitology, 2004, 20, 413-416.	1.5	4
97	ogaraK: a population genetics simulator for malaria. Bioinformatics, 2011, 27, 1335-1336.	1.8	4
98	No room for complacency on drug resistance in Africa. Nature, 2006, 444, 31-31.	13.7	2
99	Monoclonal antibodies to human hypoglossal nucleus which stain neurons and astrocytes in normal brains and brains from cases of Alzheimer-type dementia. Neuroscience, 1986, 18, 183-191.	1.1	1
100	Prenatal growth in lines of mice selected for body weight. Journal of Animal Breeding and Genetics, 1996, 113, 535-543.	0.8	1
101	Continued correspondence â€˜Will ART rollout in Africa drive an epidemic of drug-resistant HIV?â€™. Aids, 2007, 21, 258-259.	1.0	1
102	An in silico drug treatment model to assess the robustness of regional age-based dosing regimens for artemisinin-based combination therapies. Malaria Journal, 2012, 11, .	0.8	1
103	Effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: An in silico pharmacological model. Asian Pacific Journal of Tropical Medicine, 2020, 13, 366.	0.4	1
104	Effects of thyroid hormone deficiency on mice selected for increased and decreased body weight and fatness. Genetical Research, 1998, 72, 59-72.	0.3	0
105	Response to Coles: Drug resistance and drug tolerance in parasites. Trends in Parasitology, 2006, 22, 349.	1.5	0
106	The spread of antimalarial drug resistance: A mathematical model with practical implications for ACT drug policies. Nature Precedings, 2008, , .	0.1	0
107	Estimating the window of selection of antimalarial drugs using field data. Malaria Journal, 2012, 11, .	0.8	0
108	Reply to â€œParasite Strain, Host Immunity, and Circulating Blood Cells with Dead Parasites: Why Predicting Malaria Parasite Clearance Is Not a Simple Taskâ€. Antimicrobial Agents and Chemotherapy, 2016, 60, 1173-1174.	1.4	0

#	Article	IF	Citations
109	American Society of Tropical Medicine and Hygiene--49th annual meeting. IDrugs: the Investigational Drugs Journal, 2001, 4, 47-9.	0.7	0